Obesity

Madhya Pradesh's first govt obesity clinic starts at Indore's MY Hospital

Obesity surgery services were formally launched on Monday at Maharaja Yashwantrao Hospital (MYH) in Indore, making it the first such facility in the government healthcare sector in Madhya Pradesh, an official said. Obesity has emerged as a serious social problem, leading to ailments such as diabetes and high blood pressure, divisional commissioner (revenue) Sudam Khade said while inaugurating the bariatric clinic in the surgery department of MYH. "Keeping this in view, bariatric surgery services have been started at MYH. This is the first such facility of its kind in the state's government sector. Patients holding Ayushman cards will be able to avail the facility free of cost, while obesity reduction surgery in private hospitals generally costs between Rs 4-5 lakh," Khade said. Gul Afshan (30), who underwent bariatric surgery at MYH, said her weight reduced from 120 kg to 97 kg within one-and-a-half months after the operation. "This has provided relief from my diabetes problem and

Big Food pours millions into rebrands as obesity drugs reshape US demand

Peter ter Kulve, CEO of Magnum Ice Cream, said GLP-1 users continue to eat treats, but they exhibit "a stark reduction of mindless munching and binge eating"

Dr Reddy's plans to launch generic obesity drug at up to 60% discount

The company ​last month received an approval from ‌India's drug regulator ​to manufacture ‌and sell the generic version ‌of blockbuster diabetes drug Ozempic

People with obesity more likely to be hospitalised or die from infections

A major Lancet study finds adults with obesity are far more likely to be hospitalised or die from infections, linking nearly one in 10 infection deaths worldwide to excess weight

Obesity close to home: 3 in 4 Indians know someone living with obesity

A nationwide LocalCircles survey shows obesity is no longer an individual issue, with most Indians reporting obese family members or friends, underscoring India's growing public health challenge

First wave of generic semaglutide approvals opens up India market

India has entered the first phase of generic semaglutide approvals, with CDSCO clearing multiple formulations for obesity and diabetes, paving the way for lower-cost GLP-1 therapies

Confused about weight loss? Endocrinologist explains where to start right

Endocrinologist explains how to build a realistic weight-loss plan that can help you lose fat without regaining it

Weight regain after weight loss drugs is common; here's how to prevent it

Many people regain weight after stopping Ozempic and similar drugs. Expert shares why it happens and the practical steps needed to maintain weight in the long term

Why weight returns fast after stopping obesity drugs? Homeostasis explained

Here's how homeostasis, hormones and obesity drugs affect why lost weight often returns faster than expected

Stopping Ozempic or Mounjaro? The weight may come back faster than you think

New research shows people regain weight far faster after stopping obesity drugs than after dieting, with benefits fading quickly and raising questions about how long GLP-1 medicines need to be taken

How eggs can help you come off Wegovy, solve problem of weight regain

Eating eggs has been repeatedly shown to help people feel fuller for longer and eat less at later meals, including among people who are overweight or obese

GLP-1 launches inject over 2x rise in weight-loss market sales in 2025

Experts say OAds, insulin to dominate anti-diabetes market, with semaglutide patent loss leading to possible price erosion, value moderation

Obesity drugs to be new growth engine for pharma industry: Sun Pharma

Improving access to new age medicines for obesity and diabetes over the next few years would be a key enabler for the growth of the domestic pharmaceutical industry, according to Sun Pharma Managing Director Kirti Ganorkar. Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs that treat type 2 diabetes, high blood sugar, and obesity by regulating insulin production. India, known for its generic drug industry, is rapidly transforming into a major hub for the global weight management industry, amid rapid increase in obesity-led disease burden. "Improving access to GLP-1 treatments in the coming years will be a key driver for the Indian pharmaceutical industry, helping address the growing burden of lifestyle diseases such as obesity and diabetes," Ganorkar told PTI. Combined with AI-enabled digital tools for early disease detection and monitoring, and personalised medicine choices, the industry will continue to drive innovation that supports accessibility, affordability, and ..

How 2025 marked a turning point for health science and innovation

From GLP-1 drugs and personalised cancer vaccines to longevity experiments and regenerative therapies, 2025 marked a year when scientific breakthroughs reshaped healthcare and medicine

Eli Lilly, Novo Nordisk compete for lead in India's obesity drug market

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

Novo gets US nod for Wegovy pill, eyes January launch in obesity market

Novo will start selling the pill, the first of the blockbuster GLP-1 class, in the US in early January, the company said in a statement Monday

Emcure targets pan-India obesity market with Poviztra semaglutide

As GLP-1 competition heats up, Emcure is pricing semaglutide brand Poviztra at ₹8,790 a month and targeting demand beyond metros with deeper distribution in smaller cities

Biocon launches drugs for diabetes and obesity treatment in Netherlands

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

Price cuts drove market gains in November for Novo Nordisk's Wegovy

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

Harvard study finds gut-liver link that may shape future obesity treatments

A new study shows how gut-produced metabolites influence insulin response and fat metabolism, opening the door to potential future treatments for obesity and type 2 diabetes